Research programme: murine cell therapy-Huntington's disease - ReNeuronAlternative Names: MHP36; Murine cell therapy research programme-Huntington's disease - ReNeuron
Latest Information Update: 30 Sep 2003
At a glance
- Originator ReNeuron
- Mechanism of Action Tissue replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Huntington's disease
Most Recent Events
- 30 Sep 2003 Discontinued - Preclinical for Huntington's disease in United Kingdom (unspecified route)
- 03 Feb 2003 Preclinical trials in Huntington's disease in United Kingdom (unspecified route)